Bispecific Antibody-Drug Conjugates: Clinical Development and Future Directions
In the last decade, ADCs have been an emerging class of medical modalities to treat cancer by combining potent anti-cancer medicines (i.e., payloads) with monoclonal antibodies that deliver cancer medicines to the target cells. According to the market reports, the global ADC request size was valued at around 11.84 billion USD in 2024 and is […]
TROP-2 Directed Antibody-Drug Conjugates: Clinical Pipeline
In the last decade, ADCs (Antibody-Drug Conjugates) have emerged as a class of drug therapies to treat cancer by combining potent anti-cancer drugs (i.e., payloads) with specific monoclonal antibodies that deliver anti-cancer drugs to the tumor site. ADCs include three important portions comprising a monoclonal antibody, a linker (organic spacer), and an anti-cancer drug. ADCs […]